Close Menu

Quidel

Quidel said this week that John Radak will be stepping down from his role as CFO, and that Randy Steward will be taking his place effective Oct. 31.

NEW YORK (GenomeWeb News) – Life Technologies will distribute and sell Quidel's molecular diagnostic assays in Europe under an agreement announced today.

Quidel said late last week that it has received the CE Mark for the Quidel Molecular Influenza A+B real-time RT-PCR assay, the company's first commercial molecular diagnostic test.

Quidel recently submitted a 510(k) package to the US Food and Drug Administration for its first molecular diagnostic assay, a real-time PCR-based test for influenza A and B for use on Life Technologies' 7500 Fast Dx platform.

The company is eyeing a $760 million US market for its three molecular diagnostic programs: a handheld, assay platform; PCR kits for use on third-party thermal cyclers; and "Project Wildcat," an integrated sample-to-result molecular diagnostic system.

The platform will combine immiscible phase filtration sample prep with automated amplification and detection, and is expected to have initial applications in point-of-care HIV testing in remote and resource-poor areas of the world. The company also sees the platform being used for decentralized molecular testing in more developed countries.

The San Antonio-based firm also intends to file a 510(k) for clearance of the assay.

Pages

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Noel Rose, the "father of autoimmunity," has died at 92, the Washington Post reports.

According to CNN, Legionella was discovered in buildings leased by the Centers for Disease Control and Prevention as they reopened following coronavirus pandemic-related closures.

In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.